ACS降脂治疗高级班-培训课件.pptxVIP

急性冠脉综合症的降脂治疗Lipid-lowering treatment of acute coronary syndrome;Contents;ACS病理基础;ACS病理基础;ACS斑块特征;;ACS与血脂状态;ACS血脂状态;结果;ACS与血脂状态;结果;结论;ACS与血脂状态;结果;结论;;;Effects?of?atorvastatin?on?early?recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.;★A total of 3086 adults aged 18 years or older with unstable angina or non-Q-wave acute myocardial infarction. ★①To determine whether treatment with?atorvastatin ②80 mg/d atorvastatin, initiated 24 to 96 hours after an acute coronary syndrome;★Primary end point :death, nonfatal acute myocardial infarction, cardiac arrest with resuscitation, or recurrent symptomatic myocardial ischemia with objective evidence and requiring emergency rehospitalization.;Rulst;Conclusion;Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes Phase Z of the A to Z Trial;A to Z(the Aggrastat to Zocor）;Follow-up : 6～ 24months. The primary end point: Cardiovascular death Nonfatal myocardial infarction Readmission for ACS Stroke;simvastatin;Among patients with ACS, the early initiation of an aggressive simvastatin regimen resulted in a favorable trend toward reduction of major cardiovascular events.;ARMYDA Trial;153 patients scheduled for elective PCI irrespective of baseline lipid levels Randomized, double-blind ;End Points;ARMYDA Trial ;ARMYDA Trial ;pretreatment with atorvastatin significantly reduced risk of periprocedural myocardial infarction (OR 0.19, 95% CI 0.05 to 0.57). Use of β-blockers, glycoprotein IIb/IIIa inhibitors, or ACE inhibitors was not associated with risk reduction. ;ARMYDA Trial ;国内研究;;结论;国内研究;TC≥4.68mmol/L LDL-C≥2.6mmol/L TG≥1.7mmol/L HDL-C＜1.0mmol/L;结果;结论;Changping chinese traditional medical hospital